Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study
2020-12-04 08:00
Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer
2020-11-30 08:00
ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China
2020-11-19 08:30
Change in Use of Proceeds From the Global Offering for Expansion of R&D Portfolio into Hepatitis B Clinical Cure and NASH
2020-11-18 17:00
Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42,an FXR Agonist
2020-10-12 08:30
Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42,an FXR Agonist
2020-10-12 08:30
Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist
2020-09-14 08:30
Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)
2020-09-09 18:30
Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen
2020-08-20 20:00
First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody
2020-08-17 08:30
Ascletis' All-oral HCV Treatment Approved for Marketing in China
2020-07-31 08:47
Bridging Study in China Completed for NASH Drug Candidate ASC40
2020-07-20 08:30
ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial
2020-06-17 20:30
Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication
2020-05-13 18:30
Ascletis Receives IND Approval for its HIV Drug ASC09F
2020-04-13 20:00
Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020
2020-04-01 08:30
Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients
2020-03-25 08:28
Progress of the Small Sample Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
2020-03-10 17:30
Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
2020-02-27 08:00
Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA
2020-02-18 08:00
1
5
6
7
8
9